Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2019-08-22 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details changes in voting rights percentages held by BlackRock, Inc. (crossing a threshold). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a specific disclosure of shareholding changes, which is better classified as MRQ than DVA (which is for voting results) or RNS (which is a general fallback).
2019-08-22 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details changes in voting rights percentages held by BlackRock, Inc. (crossing a threshold) and provides specific figures for shares and instruments. This content directly corresponds to notifications required when major shareholdings change, which aligns with the definition of 'Major Shareholding Notification' (MRQ). Although it is a regulatory announcement, MRQ is a more specific category than the general RNS fallback.
2019-08-22 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' by BlackRock, Inc. in MorphoSys AG. It specifies the date the threshold was crossed (13 Aug 2019), the resulting percentage of voting rights (7.02%), and the breakdown of shares and instruments, referencing German securities law (WpHG). This content directly matches the definition of a notification regarding changes in significant share ownership levels, which corresponds to the Major Shareholding Notification category.
2019-08-19 English
Half-yearly financial report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Report' for the period January – June 2019. It contains comprehensive financial statements (Consolidated Statement of Profit or Loss, Balance Sheet, Cash Flows), an Interim Group Management Report, and detailed business performance analysis. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H2 2019
2019-08-08 German
MorphoSys AG Reports Second Quarter 2019 Financial Results (news with additional features)
Earnings Release Classification · 100% confidence The document explicitly states in the title and body that it reports the 'Second Quarter 2019 Financial Results' and provides detailed financial figures for Q2 2019 and the first six months of 2019, including revenues, EBIT, and EPS. This content structure is characteristic of a comprehensive periodic financial report covering a period shorter than a full year. The presence of 'Quarterly / Interim Statement' as a keyword further supports this. Therefore, it classifies as an Interim / Quarterly Report (IR), not just an Earnings Release (ER) which typically only contains highlights. Q2 2019
2019-08-06 English
MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a news release dated August 6, 2019, originating from MorphoSys AG, disseminated via DGAP (a service often used for regulatory news). The content discusses an update regarding a clinical study (B-MIND) for a drug (tafasitamab), specifically disclosing a biomarker used for patient stratification and providing updates on interim analysis timelines. This type of announcement, detailing clinical trial progress, regulatory interactions (FDA agreement), and future timelines, is characteristic of ongoing corporate and clinical development news rather than a formal periodic financial report (like 10-K or IR) or a general earnings release (ER). It is not a standard financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A/PSI). It is a specific update on drug development and study design. Since it is a news announcement about corporate/clinical progress that doesn't fit the specific categories like DIV, DIRS, or MANG, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official corporate news releases that are not otherwise classified, especially those disseminated through official news services like DGAP.
2019-08-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.